Annual FCF
$6.57 B
-$670.00 M-9.26%
31 December 2023
Summary:
AstraZeneca annual free cash flow is currently $6.57 billion, with the most recent change of -$670.00 million (-9.26%) on 31 December 2023. During the last 3 years, it has risen by +$4.37 billion (+199.45%). AZN annual FCF is now -35.32% below its all-time high of $10.15 billion, reached on 31 December 2009.AZN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$2.02 B
-$392.00 M-16.22%
30 September 2024
Summary:
AstraZeneca quarterly free cash flow is currently $2.02 billion, with the most recent change of -$392.00 million (-16.22%) on 30 September 2024. Over the past year, it has dropped by -$210.00 million (-9.40%). AZN quarterly FCF is now -42.08% below its all-time high of $3.50 billion, reached on 31 December 2009.AZN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$6.76 B
-$210.00 M-3.01%
30 September 2024
Summary:
AstraZeneca TTM free cash flow is currently $6.76 billion, with the most recent change of -$210.00 million (-3.01%) on 30 September 2024. Over the past year, it has dropped by -$220.00 million (-3.15%). AZN TTM FCF is now -33.45% below its all-time high of $10.15 billion, reached on 31 December 2009.AZN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AZN Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.3% | -9.4% | -3.1% |
| 3 y3 years | +199.4% | +91.2% | +56.7% |
| 5 y5 years | +426.6% | +165.8% | +406.5% |
AZN Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -9.3% | +199.4% | -29.4% | +189.3% | -6.6% | +79.6% |
| 5 y | 5 years | -9.3% | +1190.2% | -29.4% | +954.4% | -6.6% | +1227.5% |
| alltime | all time | -35.3% | +3380.2% | -42.1% | +182.7% | -33.5% | +812.3% |
AstraZeneca Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.02 B(-16.2%) | $6.76 B(-3.0%) |
| June 2024 | - | $2.42 B(+174.3%) | $6.97 B(+20.4%) |
| Mar 2024 | - | $881.00 M(-38.6%) | $5.79 B(-11.9%) |
| Dec 2023 | $6.57 B(-9.3%) | $1.43 B(-35.8%) | $6.57 B(-5.9%) |
| Sept 2023 | - | $2.23 B(+81.0%) | $6.98 B(+6.3%) |
| June 2023 | - | $1.24 B(-25.7%) | $6.56 B(+8.8%) |
| Mar 2023 | - | $1.66 B(-9.8%) | $6.03 B(-16.7%) |
| Dec 2022 | $7.24 B(+92.3%) | $1.84 B(+1.4%) | $7.24 B(+18.8%) |
| Sept 2022 | - | $1.82 B(+158.0%) | $6.09 B(+14.3%) |
| June 2022 | - | $705.00 M(-75.4%) | $5.33 B(+3.2%) |
| Mar 2022 | - | $2.87 B(+309.9%) | $5.17 B(+37.3%) |
| Dec 2021 | $3.76 B(+71.6%) | $700.00 M(-33.9%) | $3.76 B(-12.8%) |
| Sept 2021 | - | $1.06 B(+96.5%) | $4.31 B(-1.3%) |
| June 2021 | - | $539.00 M(-63.2%) | $4.37 B(+12.2%) |
| Mar 2021 | - | $1.47 B(+17.2%) | $3.90 B(+77.6%) |
| Dec 2020 | $2.19 B(+330.8%) | $1.25 B(+11.9%) | $2.19 B(+13.5%) |
| Sept 2020 | - | $1.12 B(+1673.0%) | $1.93 B(+22.5%) |
| June 2020 | - | $63.00 M(-126.6%) | $1.58 B(+11.2%) |
| Mar 2020 | - | -$237.00 M(-123.9%) | $1.42 B(+178.8%) |
| Dec 2019 | $509.00 M(-59.2%) | $990.00 M(+29.9%) | $509.00 M(-61.8%) |
| Sept 2019 | - | $762.00 M(-893.8%) | $1.33 B(+72.8%) |
| June 2019 | - | -$96.00 M(-91.6%) | $772.00 M(+34.5%) |
| Mar 2019 | - | -$1.15 B(-163.2%) | $574.00 M(-54.0%) |
| Dec 2018 | $1.25 B(-36.3%) | $1.81 B(+807.5%) | $1.25 B(-1122.1%) |
| Sept 2018 | - | $200.00 M(-168.0%) | -$122.00 M(-107.8%) |
| June 2018 | - | -$294.00 M(-38.0%) | $1.57 B(-12.0%) |
| Mar 2018 | - | -$474.00 M(-206.3%) | $1.78 B(-9.0%) |
| Dec 2017 | $1.96 B(+6.9%) | $446.00 M(-76.4%) | $1.96 B(-30.8%) |
| Sept 2017 | - | $1.89 B(-2433.3%) | $2.83 B(+104.3%) |
| June 2017 | - | -$81.00 M(-72.7%) | $1.39 B(+114.2%) |
| Mar 2017 | - | -$297.00 M(-122.5%) | $647.00 M(-64.7%) |
| Dec 2016 | $1.83 B(+241.6%) | $1.32 B(+196.4%) | $1.83 B(+234.1%) |
| Sept 2016 | - | $445.00 M(-154.3%) | $548.00 M(-58.3%) |
| June 2016 | - | -$820.00 M(-192.4%) | $1.31 B(-48.9%) |
| Mar 2016 | - | $887.00 M(+2363.9%) | $2.57 B(+379.5%) |
| Dec 2015 | $536.00 M(-87.6%) | $36.00 M(-97.0%) | $536.00 M(-71.4%) |
| Sept 2015 | - | $1.21 B(+177.8%) | $1.87 B(-14.7%) |
| June 2015 | - | $436.00 M(-138.0%) | $2.20 B(-18.6%) |
| Mar 2015 | - | -$1.15 B(-183.5%) | $2.70 B(-37.3%) |
| Dec 2014 | $4.31 B(-19.4%) | $1.37 B(-10.6%) | $4.31 B(-6.9%) |
| Sept 2014 | - | $1.53 B(+63.5%) | $4.63 B(+23.9%) |
| June 2014 | - | $939.00 M(+104.6%) | $3.73 B(-7.0%) |
| Mar 2014 | - | $459.00 M(-72.9%) | $4.02 B(-24.8%) |
| Dec 2013 | $5.34 B(+129.4%) | $1.69 B(+162.7%) | $5.34 B(-10.0%) |
| Sept 2013 | - | $644.00 M(-47.3%) | $5.93 B(+96.0%) |
| June 2013 | - | $1.22 B(-31.5%) | $3.03 B(+9.1%) |
| Mar 2013 | - | $1.78 B(-21.9%) | $2.77 B(+19.1%) |
| Dec 2012 | $2.33 B(-64.3%) | $2.28 B(-200.9%) | $2.33 B(-14.9%) |
| Sept 2012 | - | -$2.26 B(-333.3%) | $2.74 B(-59.0%) |
| June 2012 | - | $970.00 M(-27.5%) | $6.68 B(+7.0%) |
| Mar 2012 | - | $1.34 B(-50.3%) | $6.24 B(-4.3%) |
| Dec 2011 | $6.52 B | $2.69 B(+60.3%) | $6.52 B(-5.8%) |
| Sept 2011 | - | $1.68 B(+213.8%) | $6.93 B(-6.0%) |
| June 2011 | - | $535.00 M(-67.0%) | $7.37 B(-21.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2011 | - | $1.62 B(-47.7%) | $9.38 B(+10.4%) |
| Dec 2010 | $8.50 B(-16.3%) | $3.09 B(+45.6%) | $8.50 B(-4.5%) |
| Sept 2010 | - | $2.12 B(-16.6%) | $8.90 B(+3.0%) |
| June 2010 | - | $2.55 B(+245.9%) | $8.64 B(-3.4%) |
| Mar 2010 | - | $736.00 M(-78.9%) | $8.95 B(-11.9%) |
| Dec 2009 | $10.15 B(+115.9%) | $3.50 B(+87.3%) | $10.15 B(+13.4%) |
| Sept 2009 | - | $1.87 B(-34.4%) | $8.96 B(+6.0%) |
| June 2009 | - | $2.85 B(+46.5%) | $8.45 B(+17.4%) |
| Mar 2009 | - | $1.94 B(-15.4%) | $7.19 B(+52.9%) |
| Dec 2008 | $4.70 B(-19.3%) | $2.30 B(+69.2%) | $4.70 B(-4.6%) |
| Sept 2008 | - | $1.36 B(-14.8%) | $4.93 B(+10.9%) |
| June 2008 | - | $1.59 B(-391.4%) | $4.45 B(+27.0%) |
| Mar 2008 | - | -$547.00 M(-121.6%) | $3.50 B(-39.9%) |
| Dec 2007 | $5.83 B(-8.2%) | $2.53 B(+188.8%) | $5.83 B(+12.6%) |
| Sept 2007 | - | $875.00 M(+35.2%) | $5.18 B(-14.6%) |
| June 2007 | - | $647.00 M(-63.7%) | $6.07 B(-10.9%) |
| Mar 2007 | - | $1.78 B(-5.0%) | $6.80 B(+7.1%) |
| Dec 2006 | $6.35 B(+7.1%) | $1.88 B(+6.4%) | $6.35 B(+0.5%) |
| Sept 2006 | - | $1.76 B(+27.1%) | $6.32 B(+6.3%) |
| June 2006 | - | $1.39 B(+4.1%) | $5.95 B(-0.7%) |
| Mar 2006 | - | $1.33 B(-27.7%) | $5.99 B(+0.9%) |
| Dec 2005 | $5.93 B(+58.0%) | $1.84 B(+32.9%) | $5.93 B(+0.9%) |
| Sept 2005 | - | $1.39 B(-2.9%) | $5.88 B(+9.7%) |
| June 2005 | - | $1.43 B(+11.8%) | $5.36 B(+42.6%) |
| Mar 2005 | - | $1.28 B(-28.6%) | $3.76 B(+0.1%) |
| Dec 2004 | $3.75 B(+80.0%) | $1.79 B(+106.5%) | $3.75 B(+313.9%) |
| Sept 2004 | - | $866.00 M(-603.5%) | $907.00 M(-48.6%) |
| June 2004 | - | -$172.00 M(-113.5%) | $1.76 B(-19.6%) |
| Mar 2004 | - | $1.27 B(-220.1%) | $2.19 B(+5.2%) |
| Dec 2003 | $2.09 B(-40.3%) | -$1.06 B(-161.5%) | $2.09 B(-19.3%) |
| Sept 2003 | - | $1.72 B(+564.8%) | $2.59 B(-9.8%) |
| June 2003 | - | $259.04 M(-77.7%) | $2.87 B(-7.5%) |
| Mar 2003 | - | $1.16 B(-308.2%) | $3.10 B(-11.3%) |
| Dec 2002 | $3.49 B(+100.6%) | -$559.08 M(-127.9%) | $3.49 B(-18.7%) |
| Sept 2002 | - | $2.00 B(+308.6%) | $4.29 B(+52.1%) |
| June 2002 | - | $490.00 M(-68.6%) | $2.82 B(+17.6%) |
| Mar 2002 | - | $1.56 B(+544.6%) | $2.40 B(+38.0%) |
| Dec 2001 | $1.74 B(+98.9%) | $242.00 M(-54.5%) | $1.74 B(-283.5%) |
| Sept 2001 | - | $532.00 M(+683.2%) | -$948.66 M(-181.3%) |
| June 2001 | - | $67.92 M(-92.4%) | $1.17 B(-28.0%) |
| Mar 2001 | - | $899.08 M(-136.7%) | $1.62 B(+85.0%) |
| Dec 2000 | $875.25 M(+37.8%) | -$2.45 B(-192.5%) | $875.25 M(-73.7%) |
| Sept 2000 | - | $2.65 B(+407.7%) | $3.32 B(+391.5%) |
| June 2000 | - | $521.29 M(+236.8%) | $676.09 M(+336.8%) |
| Mar 2000 | - | $154.80 M | $154.80 M |
| Dec 1999 | $635.00 M(-68.7%) | - | - |
| Dec 1998 | $2.03 B(<-9900.0%) | - | - |
| Dec 1997 | -$8.27 M(-105.5%) | - | - |
| Dec 1996 | $148.99 M(-3.6%) | - | - |
| Dec 1995 | $154.52 M(+16.3%) | - | - |
| Dec 1994 | $132.89 M(-45.2%) | - | - |
| Dec 1993 | $242.59 M(-221.2%) | - | - |
| Dec 1992 | -$200.20 M(-267.2%) | - | - |
| Dec 1991 | $119.76 M(-55.0%) | - | - |
| Dec 1990 | $266.19 M | - | - |
FAQ
- What is AstraZeneca annual free cash flow?
- What is the all time high annual FCF for AstraZeneca?
- What is AstraZeneca annual FCF year-on-year change?
- What is AstraZeneca quarterly free cash flow?
- What is the all time high quarterly FCF for AstraZeneca?
- What is AstraZeneca quarterly FCF year-on-year change?
- What is AstraZeneca TTM free cash flow?
- What is the all time high TTM FCF for AstraZeneca?
- What is AstraZeneca TTM FCF year-on-year change?
What is AstraZeneca annual free cash flow?
The current annual FCF of AZN is $6.57 B
What is the all time high annual FCF for AstraZeneca?
AstraZeneca all-time high annual free cash flow is $10.15 B
What is AstraZeneca annual FCF year-on-year change?
Over the past year, AZN annual free cash flow has changed by -$670.00 M (-9.26%)
What is AstraZeneca quarterly free cash flow?
The current quarterly FCF of AZN is $2.02 B
What is the all time high quarterly FCF for AstraZeneca?
AstraZeneca all-time high quarterly free cash flow is $3.50 B
What is AstraZeneca quarterly FCF year-on-year change?
Over the past year, AZN quarterly free cash flow has changed by -$210.00 M (-9.40%)
What is AstraZeneca TTM free cash flow?
The current TTM FCF of AZN is $6.76 B
What is the all time high TTM FCF for AstraZeneca?
AstraZeneca all-time high TTM free cash flow is $10.15 B
What is AstraZeneca TTM FCF year-on-year change?
Over the past year, AZN TTM free cash flow has changed by -$220.00 M (-3.15%)